MAS1 and familial dilated cardiomyopathy: Pancreatic ACE2 gene therapy prevented the loss of β-cells, increased insulin production and improved fasting glycemia with no impact on insulin sensitivity (260), thus ACE2/Ang (1-7)/Mas axis acts as a pro-survival compensatory mechanism during DCM.